丙型肝炎微消除研究进展*

doi:10.3969/j.issn.1672-5069.2026.01.003

Abstract

Li Jian, Luo Lei, Yang Wenlong. Micro-elimination of hepatitis C viral infection[J]. Journal of Practical Hepatology, 2026, 29(1): 9-12.

[1] 王焱,韩军,杨美蓉.三种DAAs方案治疗慢性丙型肝炎患者两年随访研究.实用肝脏病杂志,2024,27(1):32-35.
[2] World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact. Geneva:World Health Organization, 2021.
[3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021.Geneva:World Health Organization, 2016.
[4] Collaborators P O H. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol, 2022, 7(5): 396-415.
[5] Lazarus J V, Wiktor S, Colombo M, et al. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol, 2017, 67(4): 665-666.
[6] 蒋荣猛,罗新华,窦晓光,等.丙型病毒性肝炎诊治质量改进专家共识.中华实验和临床感染病杂志(电子版), 2023, 17(6): 385-389.
[7] 彭小波, 李强, 王福超. 农村地区丙型病毒性肝炎知识知晓情况调查.中国艾滋病性病, 2021, 27(7): 770-771.
[8] 王怀, 邱倩, 袁千里, 等. 2021年北京市社区居民和医务人员丙型肝炎防治知识知晓情况调查. 疾病监测, 2023, 38(7): 854-858.
[9] 中华人民共和国国家卫生和计划生育委员会. WS 213—2018 丙型肝炎诊断.临床肝胆病杂志, 2018, 34(8): 1619-1621.
[10] 王百锁, 尤海菲, 胡婷, 等. 陕西省医务人员丙型肝炎相关知识认知情况调查.中国艾滋病性病, 2018, 24(10): 1054-1055.
[11] Health N, Commission F P, Development N, 等. 中国病毒性肝炎防治规划(2017-2020年). 中国病毒病杂志, 2018, 8(1): 1-5.
[12] 冯小飞, 丁国伟, 俞海亮, 等. 医疗机构丙型肝炎诊断治疗现况研究.中国艾滋病性病, 2020, 26(3): 247-249.
[13] 中联肝健康促进中心, 中华医学会肝病学分会, 中华医学会检验医学分会, 等. 中国丙型病毒性肝炎院内筛查管理流程(试行).临床肝胆病杂志, 2021, 37(7): 1534-1539.
[14] 国家卫生健康委办公厅, 科技部办公厅, 工业和信息化部办公厅, 等. 消除丙型肝炎公共卫生危害行动工作方案(2021-2030年). 2021-08-31.
[15] Chunmei Li, Jia Wei, Li. H. Supporting HCV elimination through medical education tours project in southwest China: AASLD, 2023.
[16] Chunfang You, Yangyang Pu, Wei Dong, et al. Collaborative in-hospital HCV micro-elimination model and call back strategy for diagnosed but untreated patients in China: AASLD, 2023.
[17] Liu L, Xu H, Hu Y, et al. Hepatitis C screening in hospitals: find the missing patients. Virol J, 2019, 16(1): 47.
[18] Huang C F, Wu P F, Yeh M L, et al. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. Clin Mol Hepatol, 2021, 27(1): 136-143.
[19] Shifu Li, Wengbing Dong, Yang Luo, et al. A government-leading multi-organization collaborative model for HCV elimination in Yuxi, Yunnan: APASL 2023.
[20] Isfordink C J, van Dijk M, Brakenhoff S M, et al. Hepatitis C elimination in the netherlands (CELINE): how nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. Eur J Intern Med, 2022, 101: 93-97.
[21] Huang JF, Hsieh MY, Wei YJ, et al. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).Hepatol Int, 2021, 16(1): 59-67.
[22] Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a nationwide eepatitis C elimination program--Georgia, April 2015. MMWR Morb Mortal Wkly Rep, 2015, 64(28): 753-757.
[23] Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, et al. Three years ofprogress toward achieving hepatitis C elimination in the country of Georgia, April 2015-March 2018. Clin Infect Dis, 2020, 71(5): 1263-1268.
[24] Averhoff F, Lazarus J V, Sergeenko D, et al. Excellence in viral hepatitis elimination - Lessons from Georgia. J Hepatol, 2019, 71(4): 645-647.
[25] Dolmazashvili E, Sharvadze L, Abutidze A, et al. Treatment of hepatitis C in primary health care in the country of Georgia. Clin Liver Dis (Hoboken), 2022, 20(5): 175-178.
[26] Olafsson S, Fridriksdottir R H, Love T J, et al. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study. Lancet Gastroenterol Hepatol, 2021, 6(8): 628-637.
[27] 罗新华, 梁跃东, 彭虹, 等. 从全球丙型肝炎微消除模式到贵州省慢性丙型肝炎健康教育模式的探索. 中华肝脏病杂志, 2020, 28(10): 816-819.
[28] Shiha G, Soliman R, Mikhail N N H, et al. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals. J Hepatol, 2021, 74(2): 303-311.
[29] 饶慧瑛, 李明阳, 魏来. 消除丙型肝炎, 我们的进展、挑战和希望. 中华肝脏病杂志, 2020, 28(10): 809-811.
[30] Bao Y, Larney S, Peacock A, et al. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. Int J Drug Policy, 2019, 70: 87-93.
[31] Martin N K, Vickerman P, Foster G R, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol, 2011, 54(6): 1137-1144.
[32] 吴涛, 林锋, 王姣, 等. 中国吸毒人群中的丙型肝炎消除:挑战、策略和经验.中华肝脏病杂志, 2022, 30(9): 1002-1006.
[33] Bartlett S R, Fox P, Cabatingan H, et al. Demonstration of near-elimination of hepatitis C virus among a prison population: the lotus glen correctional centre hepatitis C treatment project. Clin Infect Dis, 2018, 67(3): 460-463.
[34] Tejera-Pérez R J, Iglesias-Gómez A, Oliva-Oliva A, et al. Real-life experience of hepatitis C treatment in a Spanish prison. Rev Esp Quimioter, 2022, 35(3): 273-278.
[35] Marc L, Mihaescu A, Lupusoru R, et al. Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers. Int Urol Nephrol, 2023, 55(11): 2951-2958.
[36] Gan L, Wang D, Bieber B, et al. Hepatitis C prevalence, incidence, and treatment in Chinese hemodialysis patients: results from the dialysis outcomes and practice patterns study-China (2019-21). Front Med (Lausanne), 2022, 9: 910840.
[37] Huang C F, Dai C Y, Wang C W, et al. Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study. Clin Kidney J, 2023, 16(12): 2429-2436.
[38] Chaillon A, Rand E B, Reau N, et al. Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States. Clin Infect Dis, 2019, 69(11): 1888-1895.
[39] Thompson L A, Plitt S S, Doucette K, et al. Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada. J Hepatol, 2023, 79(5): 1121-1128.
[40] 刘奕杉, 张兰婷, 赵蕴玉, 等. 妊娠期妇女和儿童丙型肝炎的管理.临床肝胆病杂志, 2024, 40(4): 654-658.
[41] Torres H A, Mustafayev K, Juneau R P, et al. Implementation of universal hepatitis C virus screening in a tertiary cancer center. J Natl Compr Canc Netw, 2024, 22(2d): 1-5.
[42] American Association for the Study of Liver Diseases. The national hepatitis C elimination program-AASLD's coalition and call to action.Hepatology (Baltimore, Md.), 2023, 78(2): 371-374.
[43] 罗碧芬, 金晶兰, 饶慧瑛, 等. 磷酸依米他韦联合索磷布韦治疗慢性丙型肝炎病毒感染的有效性和安全性. 中华传染病杂志, 2019, 37(7): 420-429.
[44] Hollande C, Parlati L, Pol S. Micro-elimination of hepatitis C virus. Liver Int, 2020, 40 (Suppl 1): 67-71.

Micro-elimination of hepatitis C viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Chanjuan, Shao Jingyuan, Xu Lin. Efficacy and safety of albavir/gravir in the treatment of patients with chronic hepatitis C with underlying chronic renal disease [J]. Journal of Practical Hepatology, 2025, 28(6): 822-825.
[2]	Wang Chaojie, Xie Qun, Jiang Hai, et al. Antiviral efficacy of 3D regimen in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(6): 826-829.
[3]	Hao Shuai, Wang Ziyi, Zhang Xinyi, et al. Normalized follow-up for hepatitis C micro-elimination strategy in a general tertiary hospital [J]. Journal of Practical Hepatology, 2025, 28(5): 675-678.
[4]	Liu Zhidong, Li Wensong, Gao Zhen, et al. Efficacy of daclatasvir and asunaprevir in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(5): 679-682.
[5]	Xin Wenyuan, Li Yuwei, Wu Jun. Efficacy of dalatavir combination with asulivir in the treatment of patients with chronic hepatitis C with genotype 1b infection [J]. Journal of Practical Hepatology, 2025, 28(5): 683-686.
[6]	Fan Yuhui, Huang Supei, Hou Aimin, et al. Efficacy and safety of solimbuvir plus danorevir and ribavirin in treating patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(4): 517-520.
[7]	Lin Liquan, Bai Xiaosu, Zhang Ailan, et al. Efficacy and safety of ritonavir-boosted danoprevir with combination of sofosbuvir and ribavirin regimen in the treatment of patients with chronic hepatitis C and viral genotype 3 infection [J]. Journal of Practical Hepatology, 2025, 28(4): 521-524.
[8]	Shi Haiqun, Qian Jie, Shen Guoqian, et al. Satisfactory response to sofosbuvir and velpatasvir combination regimen in patients with hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(4): 585-588.
[9]	Wang Hao, Wang Qingyuan, Shen Qiong, et al. Satisfactory response to pegylated interferon α-2a and albavir/granrivir combination therapy in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(3): 346-349.
[10]	Qi Jing, Zhao Xiaoting, Wang Tingting, et al. Serum NoD-like receptor heat protein domain associated protein 3 level changes in patients with chronic hepatitis C undergoing sorphobuvir/dallatavir therapy [J]. Journal of Practical Hepatology, 2025, 28(2): 194-197.
[11]	Wang Fei, Liu Yingbin, Zhao Yuanyuan. Antiviral efficacy of pegylated interferon α-2a and albavir/granrivir combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(1): 40-43.
[12]	Zhu Zhonghua, Hu Junxian, Li Yan. Serumv on Willebrand factor and soluble vascular cell adhesion molecule-1 level changes in patients with hepatitis C viral infection [J]. Journal of Practical Hepatology, 2024, 27(6): 836-839.
[13]	Zhang Keli, Tong Jing, Li Changping. Antiviral efficacy of dalatavir and asulivir combination in the treatment of naïve patients with chronic hepatitis C with genotype 1b infection [J]. Journal of Practical Hepatology, 2024, 27(6): 840-843.
[14]	Li Liang, Duan Lixiang, Sun Xiaohong. Serum HCV RNA detection by NucliSens miniMag and QIAamp system [J]. Journal of Practical Hepatology, 2024, 27(6): 848-851.
[15]	Li Fang, Yang Hongfei, Zhang Qing. Virological response of patients with chronic hepatitis C to sofebuvir and redipavir combination regimen treatment [J]. Journal of Practical Hepatology, 2024, 27(5): 685-688.